Researchers at the National Institutes of Health (NIH), in Bethesda, Maryland, are testing if an investigational gene therapy using “AAV2hAQP1” increases saliva production in patients with dry mouth related to radiation therapy for head and neck cancer.
Consider participating if you:
- Are at least 18 of age
- Have a history of radiation therapy for head and neck cancer
- Experience dry mouth
- Have been free of head and neck cancer for the last 5 years and free from all other cancers for the last 3 years
You cannot participate if you:
- Are a female who is pregnant or breast feeding
- Use systemic corticosteroids such as prednisone (topical corticosteroids are allowed)
- Have an autoimmune disease that affects the salivary glands
What is involved?
- All participants will receive investigational AAv2hAQP1 gene therapy
- A medical history, physical exam, saliva collections
- A 3-day hospital stay and 10 outpatients visits over 3 years
- There is no cost for study-related medications, tests, or procedures
- Travel to and from the Clinical Center (within the U.S.) will be provided.
The NIH Clinical Center is America’s Research Hospital located in Bethesda, Maryland, on the Metro red line (Medical Center stop)
For more information, call:
Office of Patient Recruitment
NIH study # 15-D-0129
The above research study announcement posted on Cancer Survivors Network is intended to be informational in nature. The American Cancer Society does not warrant or guarantee the accuracy of the information provided and will not oversee or otherwise be involved in the conduct of the actual research study. We recommend that you consult with your health care provider if you have concerns about your health before participating in any research study. Any information you obtain through CSN announcements should not be used as a substitute for consultation with your health care provider.